

August 3, 2015

Precertification requirements for Part B drugs

HealthKeepers, Inc., on behalf of Anthem HealthKeepers Medicare-Medicaid Plan (MMP), a Commonwealth Coordinated Care plan, is adding the following new drugs to the 2015 Medicare-Medicaid Plan list of Part B injectable and infusible drugs requiring prior authorization. As of **October 1, 2015**, providers must call for prior authorization of these drugs:

1. Entyvio (vedolizumab): a monoclonal antibody that is a specific integrin receptor antagonist used for the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adult patients. (C9026)
2. Cyramza (ramucirumab): a monoclonal antibody and human vascular endothelial growth factor receptor 2 antagonist used for treatment of metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression during or after treatment with fluoropyrimidine- or platinum-containing chemotherapy. (C9025)

Noncompliance with these new requirements may result in denied claims.

For more information

If you have questions or would like more information about the topics discussed in this bulletin, please call us or visit our website:

Phone: **1-855-817-5788**

Website: **<https://mediproviders.anthem.com/va>**